ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2026
Group-level versus individualized approaches for capturing tau PET changes and clinical progression in Alzheimer's disease.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
introductionQuantification approaches based on group-level regions of interest (ROIs) are widely used for evaluating tau positron emission tomography (PET) and clinical progression in Alzheimer's disease (AD), but we hypothesize that personalized approaches better capture inter-individual heterogeneity.
methodsWe included 556 amyloid beta-positive individuals from seven cohorts (335 cognitively unimpaired [CU]; 221 cognitively impaired [CI]) with ≥ 2 [
resultsPercentage change was highest in a composite temporal ROI (temporal-meta) in CU and CI. Individualized Braak stage-based (CU) and connectivity-informed (CU/CI) approaches, and tau spatial extent (CI), performed well for sensitivity to change and clinical associations, but temporal-meta was consistently a top performer. DISCUSSION: Contrary to our hypothesis, temporal-meta quantification was most robustly associated with biological and clinical progression across disease stages, making it well suited for monitoring AD progression with tau PET.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.